Rezafungin
Chemical compound
From Wikipedia, the free encyclopedia
Rezafungin, sold under the brand name Rezzayo (by Melinta Therapeutics), is a medication used for the treatment of invasive candidiasis.[2] It is an echinocandin antifungal[1][4] that acts as a fungal β-glucan synthase inhibitor.[5]
| |
| Clinical data | |
|---|---|
| Trade names | Rezzayo |
| Other names | Biafungin; CD101 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a623021 |
| License data |
|
| Routes of administration | Intravenous |
| Drug class | Antifungal |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Excretion | Feces |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| UNII | |
| KEGG | |
| ChEBI | |
| Chemical and physical data | |
| Formula | C63H85N8O17+ |
| Molar mass | 1226.412 g·mol−1 |
Rezafungin was approved for medical use in the United States in March 2023,[1][6][5] and in the European Union in December 2023.[2][3]
Medical uses
In the United States, rezafungin is indicated in adults who have limited or no alternative options for the treatment of candidemia and invasive candidiasis.[1]
In the European Union, rezafungin is indicated for the treatment of invasive candidiasis in adults.[2]
Rezafungin, while remaining a hydrophilic compound, exhibits a volume of distribution more than twice that of caspofungin.[7] This pharmacokinetic property has supported its investigation for the treatment of deep-seated Candida infections, including osteomyelitis.[8][9]
Society and culture
Legal status
Rezafungin was approved for medical use in the United States in March 2023,[1][10][11] The FDA granted the application for rezafungin orphan drug, fast track, and priority review designations.[12]
In October 2023, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Rezzayo, intended for the treatment of invasive candidiasis in adults.[2] The applicant for this medicinal product is Mundipharma GmbH.[2] Rezafungin was approved for medical use in the European Union in December 2023.[3]
Brand names
Rezafungin is the international nonproprietary name.[13]
Rezafungin is sold under the brand name Rezzayo.[2]
